Summarized by Masters of Longevity from Startupticker.ch.
A business-focused piece about a Swiss medtech startup securing growth funding to advance its clinical program and commercial readiness; ideal for readers tracking medtech investment and commercialization milestones.
Key Takeaways
- Piomic Medical closed a USD 25 million growth financing round led by Swisscanto.
- The funding will support completion of the MAVERICKS IDE pivotal trial and U.S.
- COMS One holds FDA Breakthrough Device designation, is CE marked, and has advanced reimbursement positioning including CPT III codes.
